Onat 2010: AIP Predicts Coronary Heart Disease
Onat et al. • Atherosclerosis
Key Finding
AIP independently predicts coronary heart disease in Turkish population
Original title: “Atherogenic index of plasma as a predictor of coronary heart disease”
Plain English Summary
Turkish population study confirming AIP as an independent predictor of coronary heart disease, adding to the evidence base for this marker across different ethnic groups.
In-Depth Analysis
Background
Dr. Altan Onat and colleagues from Istanbul University published this study in Atherosclerosis (PMID: 20236645), validating AIP as an independent predictor of coronary heart disease in a Turkish population.
Study Design
Design: Prospective cohort from the Turkish Adult Risk Factor Study Population: 2,676 middle-aged adults free of coronary heart disease at baseline Follow-up: 7.8 years mean Outcome: Incident coronary heart disease events Analysis: Cox proportional hazards with adjustment for traditional risk factors
Key Findings
AIP tertiles and CHD risk:
| AIP Tertile | Events | Adjusted HR (95% CI) |
|---|---|---|
| T1 (<0.08) | 3.2% | 1.0 (reference) |
| T2 (0.08-0.26) | 5.1% | 1.42 (0.98-2.06) |
| T3 (>0.26) | 7.4% | 1.81 (1.24-2.65) |
Key finding: AIP predicted CHD independently of:
- •Total cholesterol
- •LDL cholesterol
- •Blood pressure
- •Smoking
- •Diabetes
Mechanistic Insights
The Turkish population has a distinctive lipid pattern:
- •Relatively low LDL-C
- •High triglycerides
- •Low HDL-C
- •Prevalent metabolic syndrome
AIP captures this atherogenic pattern better than LDL-C alone.
Clinical Implications
AIP has cross-ethnic validity for CHD prediction. Particularly valuable in populations where LDL-C is not the primary driver of cardiovascular risk.
Metabolic Health Perspective
This study demonstrates that AIP predicts cardiovascular events across different ethnic backgrounds. For metabolic optimization, AIP improvement tracks dietary and lifestyle interventions better than LDL-C changes.
Paradigm Relevance
How this study applies to different clinical perspectives:
Standard Medical
Conventional clinical guidelines used by most doctors
Not directly relevant to this paradigm
Research Consensus
RelevantCurrent scientific understanding, often ahead of guidelines
Metabolic Optimization
RelevantProactive targets for optimal health, not just disease absence
Study Details
- Type
- Cohort Study
Related Biomarkers
Calculate & Evaluate on Metabolicum
Original Source
DOI (Digital Object Identifier) is a permanent link to this publication. Unlike website URLs that can change, a DOI always resolves to the correct source.
Related Studies
Budoff 2024: The KETO Trial Shows No Excess Plaque in High-LDL Dieters
Budoff et al. • JACC: Advances • 2024
KETO vs control: CAC median 0 vs 1 (P=0.520); total plaque score 0 vs 1 (P=0.357); 55% vs 48% zero CAC; no correlation between LDL and plaque (r=0.12, P=0.29)
Norwitz 2021: Evidence for the Lean Mass Hyper-Responder Phenotype
Norwitz et al. • Current Developments in Nutrition • 2022
LMHR criteria (18% of sample): LDL ≥200, HDL ≥80, TG ≤70 mg/dL; LMHR BMI 22.0 vs 24.6 non-LMHR (P=1.2×10⁻¹⁰); median LDL increase 146 vs 61 mg/dL
The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate-Restricted Diets
Norwitz et al. • Metabolites • 2022
LEM proposes carbohydrate restriction in lean individuals increases hepatic VLDL secretion with enhanced lipoprotein lipase turnover, generating elevated LDL without FH genetic markers